travis mickle the ceo of kmph presented at our th annual healthcare
conference the company announced pk results in the pediatric and adolescent
aged   populations for kp in adhd which management believes could allow
for broader applicability for kp than just within pediatric patients we continue
to expect data from kp pivotal efficacy study in mid  and management
reiterated timing of a potential nda submission for kp in q on apadaz
management continues to seek a partner for the product and remains coitted to
executing a unique coercialization strategy focusing on partnerships with pbms
to drive volume at prices more in line with generics' during the presentation kmph
also mentioned it continues to seek partnerships that leverage its lat platform